Crown Bioscience Logo

3D Ex Vivo Patient Tissue Platform


A 3D high content imaging-based screening assay for evaluating monotherapy and combination drug responses in patient tumors with endogenous immune cell populations intact.


Patient-relevant translational systems that better mimic the heterogeneity and molecular/genetic complexity of human tumors to:

  • Understand drug effects on native TME
  • Gain more accurate insights beyond general cell viability (i.e. CTG)
  • Evaluate immuno-oncology (I/O) drugs including immune checkpoint inhibitors (ICI) with endogenous immune cells
  • Make better informed decisions about progressing into the clinic with more data
  • The most patient-relevant ex vivo system available
    • Derived from fresh patient tumor samples processed within 24 hours of receipt
    • Preserves native TME with endogenous immune cells, fibroblasts, and other stromal components
    • Patient-specific plate: 50-300 patient tumor tissues directly seeded in hydrogel matrix in 384-well format
  • Drug effects including tumor killing and immune cell proliferation are measured by phenotypic high content imaging (HCI) analysis


Ex vivo testing protocols established for a wide range of solid tumors representing patient tumor biology

  • Physiologically Relevant 3D models
    Leveraging patient- and PDX-derived tissue organoid models matched to patient data, 3D spheroids from CDX and PDX material, and patient samples
  • High-Throughput, Imaging-Based platform
    Automated high content microscopy used to image 3D cultures grown in 384-well plates to enable efficient combination and dosing regimen evaluations
  • 3D Phenotypic High Content Image Analysis
    Image analysis with proprietary software developed to measure phenotypic changes induced by small molecules and new therapeutic modalities in 3D
  • Reliable, Reproducible Data
    Tumor killing and immune cell proliferation are accurately measured via phenotypic analysis to support important R&D decisions

For more information

Tags: #oncology, biomarker analysis, biomarker detection, CDX, cell line authentication, cell line screening, cell line-derived xenograft, DMPK, drug development, drug screening, high content imaging, humanized models, immune-oncology, inflammatory diseases, organoids, patient derived xenograft, PDX models, Preclinical efficacy, syngeneic models, toxicology, tumours